The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To compare retrospectively the role of (18)F-FDG SPECT-CT and conventional imaging in the detection of recurrence and metastases in postoperative breast cancer patients with elevated level of tumor markers, and to evaluate the impact of (18)F-FDG SPECT-CT on the management of breast cancer patients.</p><p><b>METHODS</b>(18)F-FDG SPECT-CT was performed in 35 breast cancer patients with suspected recurrence based on elevated level of serum tumor markers. Chest, abdomen and pelvic CT were performed in all patients and whole-body bone scan was performed in only 21 patients. The final diagnosis of recurrent breast cancer was confirmed by either pathology or observation by imaging during the follow-up for more than 1 year.</p><p><b>RESULTS</b>Among the 35 patients, the final diagnosis of recurrence or metastasis was established in 19 patients. Of the 114 sites of increased FDG uptake, 93 were interpreted as malignant and 21 as benign. On site-based analysis, the sensitivity, specificity, accuracy, positive and negative predictive values were 93.1%, 55.6%, 84.2%, 87.1% and 71.4%, respectively, for (18)F-FDG SPECT-CT, and 80.5%, 60.5%, 75.6%, 80.2% and 65.1%, respectively, for conventional imaging. On the patient-based analysis, the sensitivity, specificity, accuracy, positive and negative predictive values were 84.2%, 62.5%, 74.3%, 72.7% and 76.9%, respectively, for (18)F-FDG SPECT-CT, and 74.1%, 67.6%, 70.6%, 68.3% and 73.9%, respectively, for conventional imaging. The results of (18)F-FDG SPECT-CT led to changes in the subsequent clinical management of 40.0% of these patients.</p><p><b>CONCLUSION</b>In postoperative breast cancer patients with elevated level of tumor markers during the follow-up, (18)F-FDG SPECT-CT is more sensitive for detecting recurrence and metastases than conventional imaging.</p>

Expression of sexual hormon receptors in prostatic cancer tissues / 中华男科学杂志

<p><b>OBJECTIVE</b>To investigate the relationship between the androgen receptor (AR), oestrogen receptor( ER) and progesterone receptor (PR) by assaying the distributions of these three receptors in the both benign prostate hyperplasia (BPH) and prostatic cancer (PCa) tissues, then to explore the difference of the effects of hormonal treatment between the AR positive and AR negative in PCa patients.</p><p><b>METHODS</b>To observe AR, PR and ER expressions in 30 cases of BPH and 32 cases of PCa tissues by DAKO Envision methods.</p><p><b>RESULTS</b>There were 22 AR positive, 10 ER positive and 6 PR positive cases in 30 BPH patients, and there were 18 AR positive, 14 ER positive and 2 PR positive in 32 PCa patients. There was no significant difference between the two groups. The survival time was 6.41 and 4.28 years for the AR positive and AR negative respectively in 30 PCa patients. The AR positive patients lived longer than the AR negative (P < 0.05).</p><p><b>CONCLUSION</b>These three receptors cant result in PCa and the effects of hormonal treatment on AR negative PCa patients is not certain.</p>

Therapeutic Evaluation of ~(18)F-FDG Coincidence SPECT Imaging in Malignant Lymphoma / 上海第二医科大学学报

Objective To study the clinical value of ~(18)F-fluorodeoxyglucose(~(18)F-FDG) coincidence SPECT imaging in the therapy of malignant lymphoma. Methods Serial ~(18)F-FDG SPECT imaging were performed on 42 patients with malignant lymphoma before and after treatment.The results were compared with other conventional imaging.Patients were divided into two groups. Twenty-seven new-diagnosed patients(group Ⅰ) and 15 operated patients(group Ⅱ) had ~(18)F-FDG imaging pre-and post-chemotherapy. Results(In group Ⅰ,) 15 cases(achieved) clinical remission,five cases relapsed and one case progressed.In group Ⅱ,tumor residues were detected in four patients,and one patient relapsed. Conclusion Serial ~(18)F-FDG imaging during treatment is very useful for therapeutic evaluation in malignant lymphoma.

Preliminary study on treatment of partial androgen deficiency in aging males with Jingui Shenqi Pill / 中国结合医学杂志

<p><b>OBJECTIVE</b>To observe the efficacy and safety of Jingui Shengqi Pill in treating partial androgen deficiency in aging males (PADAM), and to explore the new approach in improving the quality of life in PADAM patients.</p><p><b>METHODS</b>Forty patients with PADAM were treated with JSP, the efficacy was evaluated with international index of erectile function (IIEF) scoring, PADAM questionnaire scoring, hormone, prostatic specific antigen (PSA), etc., and the data before treatment were compared with those after treatment in the same group.</p><p><b>RESULTS</b>After 3 months of treatment, PADAM scoring and IIEF scoring were all significantly improved. Symptoms regarding physical ability, vasomotion, and psychical and mental condition all got improved more markedly than symptoms regarding sexual hypofunction. The serum level of testosterone was 3.85 +/- 0.36 before treatment and 5.02 +/- 0.83 after treatment (P < 0.05); luteinizing hormone of 7.33 +/- 2.14 and 4.84 +/- 1.43 (P < 0.01), follicle-stimulating hormone of 10.22 +/- 4.48 and 6.47 +/- 3.28 (P < 0.01), respectively. The level of PSA failed to change significantly (1.94 +/- 0.55 and 2.06 +/- 0.47, P > 0.05).</p><p><b>CONCLUSION</b>JSP is effective and safe in treating PADAM, the mechanism of it is different from supplementing extrinsic androgen. It may have produced the effect by means of favorably regulating the condition of sex hormone to improve the balance of pituitary-sex gland axis, so it has more extensive clinical application.</p>